We are live on
!
Find out more
UOC
UBS O'Connor Portfolio holdings
AUM
$3.76B
1-Year Est. Return
62.41%
This Fund
S&P 500
This Quarter
Est. Return
+8.61%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$5.42B
AUM Growth
-$3.38B
(-38%)
Cap. Flow
-$3.75B
Cap. Flow
% of AUM
-69.25%
Top 10 Holdings %
Top 10 Hldgs %
40.63%
Holding
1,042
New
84
Increased
109
Reduced
414
Closed
284
Avg Time Held Equity + Options
3.7
quarters
Top 10 Avg Time Held Equity + Options
0.5
quarters
Top 20 Avg Time Held Equity + Options
0.8
quarters
Avg Time Held Equity only
3.7
quarters
Top 10 Avg Time Held Equity only
0.5
quarters
Top 20 Avg Time Held Equity only
0.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$184M |
| 2 |
STOR
STORE Capital Corporation
STOR
|
+$172M |
| 3 |
First Horizon
FHN
|
+$107M |
| 4 |
COUP
Coupa Software Incorporated
COUP
|
+$96.9M |
| 5 |
AAWW
Atlas Air Worldwide Holdings, Inc.
AAWW
|
+$64.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$572M |
| 2 |
ZEN
ZENDESK INC
ZEN
|
+$456M |
| 3 |
AVLR
Avalara, Inc.
AVLR
|
+$373M |
| 4 |
SWCH
Switch, Inc. Class A Common Stock
SWCH
|
+$271M |
| 5 |
Rogers Corp
ROG
|
+$219M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 25.7% |
| 2 | Technology | 18.31% |
| 3 | Healthcare | 15.11% |
| 4 | Miscellaneous | 11.75% |
| 5 | Real Estate | 10.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
276
Valmont Industries
VMI
$9.11B
| $3.14M | 0.06% |
+9,492
| New | +$3.01M |
2022 Q4
0 quarters
|
|
277
American Homes 4 Rent
AMH
$11B
| $3.12M | 0.06% |
103,398
-40,459
| -28% | -$1.28M |
2020 Q2
10 quarters
|
|
278
Norwegian Cruise Line
NCLH
$6.95B
| $3.03M | 0.06% |
247,861
| – | – |
2021 Q3
5 quarters
|
|
|
RFP
279
DELISTED
Resolute Forest Products Inc.
RFP
| $3.03M | 0.06% |
+140,498
| New | +$2.94M |
2022 Q4
0 quarters
|
|
280
Protagonist Therapeutics
PTGX
$9.68B
| $3.02M | 0.06% |
276,473
+43,653
| +19% | +$368K |
2022 Q1
3 quarters
|
|
281
AnaptysBio
ANAB
$1.38B
| $3M | 0.06% |
96,980
+15,312
| +19% | +$432K |
2022 Q1
3 quarters
|
|
|
SVFA
282
DELISTED
SVF Investment Corp. Class A Ordinary Shares
SVFA
| $2.99M | 0.06% |
295,451
-2,898
| -1% | -$29.1K |
2021 Q2
6 quarters
|
|
283
American Airlines Group
AAL
$8.41B
| $2.98M | 0.05% |
+234,100
| New | +$3.17M |
2022 Q4
0 quarters
|
|
284
DELISTED
Sound Point Acquisition Corp I, Ltd Class A Ordinary Share
SPCM
| $2.97M | 0.05% |
273,069
-2,672
| -1% | -$27.4K |
2022 Q2
2 quarters
|
|
285
Ionis Pharmaceuticals
IONS
$7.44B
| $2.96M | 0.05% |
78,370
+23,873
| +44% | +$1M |
2022 Q1
3 quarters
|
|
286
DELISTED
The AZEK Co
AZEK
| $2.95M | 0.05% |
145,339
-366,092
| -72% | -$6.77M |
2021 Q4
4 quarters
|
|
287
Public Storage
PSA
$54.3B
| $2.94M | 0.05% |
10,474
-40,840
| -80% | -$11.9M |
2021 Q4
4 quarters
|
|
288
Agenus
AGEN
$344M
| $2.92M | 0.05% |
62,057
+22,418
| +57% | +$1.14M |
2022 Q1
3 quarters
|
|
|
LVAC
289
DELISTED
LAVA Medtech Acquisition Corp. Class A Common Stock
LVAC
| $2.92M | 0.05% |
283,573
-2,775
| -1% | -$28.1K |
2022 Q1
3 quarters
|
|
290
Accel Entertainment
ACEL
$894M
| $2.91M | 0.05% |
378,313
-3,718
| -1% | -$31.9K |
2020 Q1
11 quarters
|
|
|
APN
291
DELISTED
Apeiron Capital Investment Corp
APN
| $2.91M | 0.05% |
283,573
-2,775
| -1% | -$28.3K |
2022 Q1
3 quarters
|
|
292
DELISTED
SpringWorks Therapeutics
SWTX
| $2.9M | 0.05% |
111,615
+21,622
| +24% | +$533K |
2022 Q1
3 quarters
|
|
293
DELISTED
AP Acquisition Corp
APCA
| $2.88M | 0.05% |
278,023
-2,721
| -1% | -$27.9K |
2022 Q1
3 quarters
|
|
294
Southland Holdings
SLND
$45.8M
| $2.87M | 0.05% |
283,573
-2,775
| -1% | -$27.9K |
2022 Q1
3 quarters
|
|
|
LEGA
295
DELISTED
Lead Edge Growth Opportunities, Ltd Class A Ordinary Shares
LEGA
| $2.85M | 0.05% |
282,468
-2,764
| -1% | -$27.7K |
2021 Q2
6 quarters
|
|
296
NVR
NVR
$15.5B
| $2.85M | 0.05% |
618
+423
| +217% | +$1.86M |
2022 Q2
2 quarters
|
|
297
DELISTED
APx Acquisition Corp. I Class A Ordinary Share
APXI
| $2.85M | 0.05% |
278,023
-2,721
| -1% | -$27.8K |
2022 Q1
3 quarters
|
|
|
STET
298
DELISTED
ST Energy Transition I Ltd.
STET
| $2.84M | 0.05% |
278,023
-2,721
| -1% | -$27.5K |
2022 Q1
3 quarters
|
|
299
DELISTED
Mersana Therapeutics
MRSN
| $2.83M | 0.05% |
19,316
+4,256
| +28% | +$719K |
2022 Q1
3 quarters
|
|
|
HMA
300
DELISTED
Heartland Media Acquisition Corp.
HMA
| $2.83M | 0.05% |
278,023
-2,721
| -1% | -$27.5K |
2022 Q1
3 quarters
|
|
Similar funds
FNBT
ACI
RC
A
CGL
CB
JCM
MPM
UBS O'Connor's Q4 2022 Portfolio in Review
As of Q4 2022, UBS O'Connor held 1,042 positions worth $5.42B, down 38% from $8.8B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
UBS O'Connor withdrew a net $3.75B in Q4 2022, closing 284 positions and reducing 414 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $572M position sold in full.
By sector, the portfolio is most concentrated in Financials at 26% of assets, up from 20% a quarter earlier, followed by Technology and Healthcare.
Against the trend, UBS O'Connor opened a new position in Coupa Software Incorporated worth $128M.
- UBS O'Connor's largest Q4 2022 buy was Coupa Software Incorporated: 1,619,333 shares worth $128M.
- UBS O'Connor added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022, an estimated $184M increase.
- UBS O'Connor's biggest Q4 2022 reduction was Rogers Corp, cutting an estimated $219M.
- UBS O'Connor fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $572M.
- UBS O'Connor's ten largest holdings make up 41% of its $5.42B portfolio in Q4 2022.
- UBS O'Connor opened 84 new positions and closed 284 in Q4 2022.
- UBS O'Connor's portfolio value fell 38% quarter-over-quarter to $5.42B.
Based on UBS O'Connor's 13F filing for Q4 2022, filed 14 Feb 2023.